Leukemia, MyeloidAcute DiseasePiperazinesPyrimidinesQuinolonesThionucleotidesAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsDrug EvaluationAbstract The standard therapy for acute myeloid leukemia (AML) has not changed meaningfully for the past four decades. Improvements in supportive care and ...
Acute myeloid leukemia (AML) is the second most common form of leukemia and the most frequent cause of leukemia-related deaths in the United States. The incidence of AML increases with advancing age and the prognosis for patients with AML worsens substantially with increasing age. Many older pati...
combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia 1999; 13: 843–9
Despite the introduction of novel combination chemotherapies in acute myeloid leukemia (AML), cytarabine (AraC) remains the primary component of AML therapy. The chemotherapy for inducing remission consists of a seven-day regular dose of AraC and a three-day regular dose of anthracyclines. This reg...
TP53 and DNA-PK as potential biomarkers for enhanced efficacy of Olaparib in colorectal cancer Do Yeon Kim Hyeseon Yun Dong-Hoon Jin Research 16 May 2025 Evaluation of anti-leukemic activity and underlying mechanisms of the novel GSPT1 degrader AB138 in acute myeloid leukemia Liqiang Wang ...
In June, HYML-122, a drug targeting acute myeloid leukemia, was approved by the SDA for a clinical trial. It was developed by a research team from Hefei Institute of Physical Science. If the trial is successful, the drug will be put into clinical use in five years. ...
Acute myeloid leukemia ANG: Angiopep-2 APL: Acute promyelocytic leukemia ATF: Amino-terminal fragment ATO: Arsenic trioxide ATRA: All-trans retinoic acid BBB: Blood–brain barrier BHD: Bai-Hu decoction BSA: Bovine serum albumin BSM: Basilicum seed mucilage ...
et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 11, 653–668 (2009). Article CAS PubMed Google Scholar Van Tendeloo, V. F. et al. ...
-Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy Usual Adult Dose of Gleevec for Acute Lymphoblastic Leukemia: ...
CD47 is an independent prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Blood (ASH Annual Meeting Abstracts), 112: 766, 2008. 19. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic ...